secwatch / observer
8-K filed February 10, 2023, 6:59 PM ET ticker LFMD CIK 0000948320
leadership confidence high sentiment neutral materiality 0.45

LifeMD appoints Dr. Joan LaRovere to Board; Kathleen E. Walsh resigns

LifeMD, Inc.

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. Joan LaRovere

Director
LFMD · LifeMD, Inc.
Effective
2023-02-09
Filed
February 10, 2023, 6:59 PM ET
On February 9, 2023, LifeMD, Inc. (the “Company”) appointed Dr. Joan LaRovere to the board of directors (the “Board”) of the Company.
Departed

Kathleen E. Walsh

Director
LFMD · LifeMD, Inc.
Effective
2023-02-09
Filed
February 10, 2023, 6:59 PM ET
Effective February 9, 2023, Kathleen E. Walsh voluntarily resigned from her position as a member of the Board in connection with her appointment as the Secretary of the Executive Office of Health and Human Services for the Commonwealth of Massachusetts.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Dr. Joan LaRovere was appointed as Director at LifeMD, Inc..

Action
appointed
Role
Director
Exact text from the filing
On February 9, 2023, LifeMD, Inc. (the “Company”) appointed Dr. Joan LaRovere to the board of directors (the “Board”) of the Company.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 1.0

Kathleen E. Walsh resigned as Director at LifeMD, Inc..

Action
resigned
Role
Director
Exact text from the filing
Effective February 9, 2023, Kathleen E. Walsh voluntarily resigned from her position as a member of the Board in connection with her appointment as the Secretary of the Executive Office of Health and Human Services for the Commonwealth of Massachusetts.
View on SEC.gov

LifeMD, Inc. filing history →

Source: SEC EDGAR
accession 0001493152-23-004330
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.